{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:22:41Z","timestamp":1793467361442,"version":"4.5.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"13","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with large B-cell lymphoma (LBCL) that fail to achieve a complete response (CR) or who relapse early after anthracycline-containing immunochemotherapy (IC) have a poor prognosis and are commonly considered to have \u201cprimary refractory disease.\u201d However, different definitions of primary refractory disease are used in the literature and clinical practice. In this study, we examined variation in the time to relapse used to define refractory status and association with survival outcomes in patients with primary refractory LBCL in a single-center prospective cohort with validation in an independent multicenter cohort. Patients with newly diagnosed LBCL were enrolled in the Molecular Epidemiological Resource cohort (MER; N\u00a0= 949) or the Lymphoma Epidemiology of Outcomes cohort (LEO; N\u00a0= 2755) from September 2002 to May 2021. Primary refractory LBCL was defined as no response (stable disease [SD]) or progressive disease (PD) during, or by the end of, frontline (1L) IC (primary PD; PPD); partial response at end of treatment (EOT PR); or relapse within 3 to 12\u00a0months after achieving CR at EOT to 1L IC (early relapse). In the MER cohort, patients with PPD had inferior overall survival (OS; 2-year OS rate: 15% MER, 31% LEO) when compared with other subgroups considered in defining primary refractory disease, EOT PR (2-year OS rate: 38% MER, 50% LEO) and early relapse (2-year OS rate: 44% MER, 58% LEO). Among patients receiving 1L IC with curative intent, we identified that patients with PPD are the key subgroup with poor outcomes. We propose a definition of primary refractory LBCL as SD or PD during, or by the end of, 1L treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012760","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T14:05:15Z","timestamp":1714140315000},"page":"3402-3415","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Defining primary refractory large B-cell lymphoma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3174-8877","authenticated-orcid":false,"given":"Allison M.","family":"Bock","sequence":"first","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"},{"name":"2Department of Hematology and Hematologic Malignancies, Huntsman Cancer Institute\/University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Mwangi","sequence":"additional","affiliation":[{"name":"3Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi","family":"Khurana","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[{"name":"3Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Ayers","sequence":"additional","affiliation":[{"name":"4Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[{"name":"5Division of Oncology, Washington University in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-6481","authenticated-orcid":false,"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Medical Oncology, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-9932","authenticated-orcid":false,"given":"Carla","family":"Casulo","sequence":"additional","affiliation":[{"name":"8Division of Hematology\/Oncology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"9Division of Hematology, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7891-9891","authenticated-orcid":false,"given":"Umar","family":"Farooq","sequence":"additional","affiliation":[{"name":"10Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabarish","family":"Ayyappan","sequence":"additional","affiliation":[{"name":"10Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanner","family":"Reicks","sequence":"additional","affiliation":[{"name":"3Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"4Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Hematologic Malignancies, Huntsman Cancer Institute\/University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-8610","authenticated-orcid":false,"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"4Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"issue":"4","key":"2024070913110081500_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024070913110081500_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"19","key":"2024070913110081500_bib3","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2024070913110081500_bib4","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00277-015-2467-z","article-title":"Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment","volume":"94","author":"Hitz","year":"2015","journal-title":"Ann Hematol"},{"issue":"1","key":"2024070913110081500_bib5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.14813","article-title":"Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy","volume":"179","author":"Farooq","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"2024070913110081500_bib6","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","article-title":"BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma","volume":"13","author":"Mills","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024070913110081500_bib7","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/1097-0142(20010415)91:8<1557::AID-CNCR1165>3.0.CO;2-4","article-title":"Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens","volume":"91","author":"Villela","year":"2001","journal-title":"Cancer"},{"issue":"23","key":"2024070913110081500_bib8","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024070913110081500_bib9","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood.V96.7.2399","article-title":"High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis","volume":"96","author":"Kewalramani","year":"2000","journal-title":"Blood"},{"issue":"18","key":"2024070913110081500_bib10","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024070913110081500_bib11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3109\/10428194.2011.643404","article-title":"Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors","volume":"53","author":"Telio","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"27","key":"2024070913110081500_bib12","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2024070913110081500_bib13","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2024070913110081500_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/CCO.0000000000000209","article-title":"Primary refractory diffuse large B cell lymphoma in the rituximab era","volume":"27","author":"Sarkozy","year":"2015","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"2024070913110081500_bib15","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1182\/blood.2020007939","article-title":"Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?","volume":"137","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2024070913110081500_bib16","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2024070913110081500_bib17","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10343","key":"2024070913110081500_bib18","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"26","key":"2024070913110081500_bib19","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024070913110081500_bib20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024070913110081500_bib21","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/16078454.2022.2147916","article-title":"External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival","volume":"27","author":"Warnnissorn","year":"2022","journal-title":"Hematology"},{"issue":"11","key":"2024070913110081500_bib22","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2014.06.036","article-title":"Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation","volume":"20","author":"Hamadani","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2024070913110081500_bib23","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/ije\/dyx119","article-title":"Cohort profile: the lymphoma specialized program of research excellence (SPORE) molecular epidemiology resource (MER) cohort study","volume":"46","author":"Cerhan","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"1","key":"2024070913110081500_bib24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"Suppl 1","key":"2024070913110081500_bib25","article-title":"The lymphoma epidemiology of outcomes (LEO) cohort study reflects the demographics and subtypes of patients diagnosed with non-Hodgkin lymphoma in the United States","volume":"132","author":"Flowers","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2024070913110081500_bib26","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024070913110081500_bib27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2024070913110081500_bib28","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"2024070913110081500_bib29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/EDBK_175437","article-title":"Understanding the new WHO classification of lymphoid malignancies: why it's important and how it will affect practice","volume":"37","author":"Jaffe","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"2024070913110081500_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2024070913110081500_bib31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bjh.14453","article-title":"Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era","volume":"176","author":"Vardhana","year":"2017","journal-title":"Br J Haematol"},{"issue":"9","key":"2024070913110081500_bib32","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3324\/haematol.2020.275958","article-title":"Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"106","author":"Duell","year":"2021","journal-title":"Haematologica"},{"issue":"7","key":"2024070913110081500_bib33","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"Suppl 16","key":"2024070913110081500_bib34","article-title":"Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy","volume":"41","author":"Nastoupil","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2024070913110081500_bib35","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2024070913110081500_bib36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.17738","article-title":"The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma","volume":"195","author":"Lutfi","year":"2021","journal-title":"Br J Haematol"},{"issue":"13","key":"2024070913110081500_bib37","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/bloodadvances.2020004155","article-title":"Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas","volume":"5","author":"Liebers","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2024070913110081500_bib38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"Suppl 16","key":"2024070913110081500_bib39","article-title":"ZUMA-23: a global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma","volume":"41","author":"Westin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"2024070913110081500_bib40","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.1182\/blood-2022-156497","article-title":"Molecular landscape of primary refractory DLBCL","volume":"140","author":"Bock","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2024070913110081500_bib41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2024070913110081500_bib42","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.2217\/fon-2021-0532","article-title":"Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy","volume":"17","author":"McBride","year":"2021","journal-title":"Future Oncol"},{"issue":"1","key":"2024070913110081500_bib43","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1186\/s12885-021-08068-0","article-title":"Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions\/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)","volume":"21","author":"Yokoyama","year":"2021","journal-title":"BMC Cancer"},{"issue":"6","key":"2024070913110081500_bib44","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3402\/2233967\/blooda_adv-2024-012760-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3402\/2233967\/blooda_adv-2024-012760-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T09:12:28Z","timestamp":1720516348000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/13\/3402\/515908\/Defining-primary-refractory-large-B-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":44,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012760","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]}}}